Canada: New Patented Medicines Prices Review Board (PMPRB) Regulations Open For Comment

Last Updated: December 15 2017
Article by Anita Nador

Most Read Contributor in Canada, October 2018

The Canadian government recently published its proposed Regulations Amending the Patented Medicines Regulations (the "Regulations") for coming into force January 1, 2019. The proposed Regulations are currently open for public consultation. The Office of Pharmaceuticals Management Strategies, Strategic Policy Branch, Health Canada will receive comments from interested persons until February 15, 2018.

The Regulations are pursuant to provisions of the Patent Act which are administered by the Patented Medicines Prices Review Board ("PMPRB") The PMPRB is best known for its mandate relating to its patented drug price reporting requirements and protecting consumers against excessive pricing of patented medicines. The proposed Regulations:

  1. change the list of comparator countries under section 4(1)(f)(iii) of the Regulations by removing the United States and Switzerland and by adding Australia, Belgium, Japan, Netherlands, Norway, Republic of Korea and Spain. France, Germany, Italy, Sweden and the United Kingdom remain on the list.

    The PMPRB's position is  that the selected countries are "better" comparators to the Canadian market and the increase of the number of countries in the Schedule minimizes the impact of outlier countries or when pricing information is not available for a particular jurisdiction.  The removal of the United States and absence of Mexico, two of Canada's largest trading partners is notable, as is the selection of countries that in general have lower drug prices than Canada without regard to impact on accessibility to new medicines in those jurisdictions. 

  2. modify reporting requirements to enable the PMPRB to assess the price net of all domestic price adjustments (i.e. the "actual" price or revenue obtained by the Patentee).  So rebates and discounts to any third parties (e.g. public and private insurers, including any rebates/discounts pursuant to any product listing agreements (PLAs)) must be factored into the reported price.

    The PMPRB notes that due to confidential price negotiations between manufacturers and payors, there is an increasing discrepancy between the list price and actual price of a drugs in the market. The PMPRB states that it would keep this information confidential. This is consistent with the practices of the provincial rulings regarding agreements with the provinces, however, there should be assurances that the information would not be inadvertently accessible through, for instance, Section 21.1(3) of the Food and Drugs Act, where the "Minister" may disclose confidential business information about a therapeutic product without notifying the person to whose business or affairs the information relates or obtaining their consent, if the purpose of the disclosure is related to the protection or promotion of human health or the safety of the public and the disclosure is to...or (c) a person who carries out functions relating to the protection or promotion of human health or the safety of the public. 

  3. add GDP (gross domestic product) in Canada, size of the market in Canada and other countries and pharmacoeconomic value into the consideration of excessive price. Cost-utility analysis prepared by a publicly funded Canadian organization (e.g. CADTH), if published,  that report cost per quality-adjusted life year must be provided within 30 days of first sale or if not published  within 30 days from publication. For drugs on the market on January 1, 2019, any such published analysis must be provided within 30 days of the coming into force of the regulations or if not yet published within 30 days of publication. Further, market size information must be provided within 30 days of the first offer for sale in Canada and kept up to date. Any modification must be provided within 30 days of the modification. Similarly, for medicines first offered for sale in Canada between January 1, 2016 to December 31, 2018, the most recent market size information must be provided within 30 days of January 1, 2019   with similar obligations to update the information  if there are any changes.

    PMPRB states that adding these factors, better enables them to assess the value of a medicine to a patient, the number of patients who may benefit and the ability of a country to pay.

    It would be useful for the PMPRB to provide working examples of how these new factors will impact their price determinations.

    Further,  these changes to the Regulations increase reporting requirements and may open up drug prices that were compliant prior to the Regulations to reassessment.

  4. reduce reporting requirements for patented veterinary and over-the counter medicines which would only need to report price and sales and identity information at the request of the PMPRB (within 30 days of the request and for each six month period for two years following the request) and extends this to medicines that comprise a controlled substance or are a radiopharmaceutical and/or a biologic and to patented generic medicines (approved by means of an ANDS). Such drugs are similarly exempt from the continual reporting of cost-utility analysis information unless requested by the Board.

    The PMPRB's position is that excessive pricing is not as much of concern with the drugs they have exempted. It is interesting to note that this is in light of the fact that Canadian generic drug prices are some of the highest in the world, even by the PMPRB's own study1. The carve out is inconsistent with the wide net that the PMPRB has cast with regard to their jurisdiction over patented medicines (even a patent with the "slenderest thread" would be caught). On the one hand they are assuming a diminished value of a patent to a generic manufacturer but on the other hand not providing the same consideration to the value of a patent to a brand name manufacturer. While drugs that have patents that are listable or are listed on the Patent Register under the Patented Medicines (Notice of Compliance) Regulations may be more valuable and may have a greater impact on price, a patent on a product that has gone generic, irrespective of whether the drug was approved through a "New Drug Submission" (NDS) or an "Abbreviated New Drug Submission" ("ANDS"), is likely to have less of an impact. There are other situations where a patent to a brand name manufacturer may have diminished value or impact on pricing yet they are not afforded the same lessening of reporting requirements under the Regulations.

To summarize, the proposed Regulations increase reporting requirements of brand name patentees while lessening the reporting obligations of generic manufacturers. Further, the PMPRB may take the new Regulations as an opportunity to reassess the price of a previously price compliant drug exposing a company to an excessive price determination.  Manufacturers will need to adapt their internal reporting systems to the new regime and would be well advised to reassess and confirm the price of their drugs prior to coming into force of the Regulations.  


1 See, Generic Drugs in Canada: international Price Comparisons and Potential Cost Savings, 2011 ISBN: 978-1-100-19410-3 , Cat. No.: H82-9/2011E-PDF, September 2011 and Generics 360 – Generic Drugs in Canada, 2014, ISSN: 2369-9043, Catalogue number: H79-9E-PDF, February 2016

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions